|1.||Bates, Susan E: 24 articles (07/2015 - 03/2002)|
|2.||Piekarz, Richard L: 16 articles (07/2015 - 03/2002)|
|3.||Prince, H Miles: 12 articles (07/2015 - 11/2009)|
|4.||Figg, William D: 11 articles (08/2013 - 03/2002)|
|5.||Nichols, Jean: 8 articles (08/2015 - 01/2009)|
|6.||Fojo, Tito: 8 articles (07/2015 - 03/2002)|
|7.||Steinberg, Seth M: 8 articles (07/2015 - 06/2006)|
|8.||Robey, Robert W: 8 articles (05/2015 - 03/2002)|
|9.||Frye, Robin: 7 articles (08/2013 - 02/2009)|
|10.||Wright, John J: 7 articles (12/2012 - 06/2006)|
01/01/2014 - "Our in vitro study suggested that combination of FK228 and RXM may be helpful for enhancing tumor killing effects. "
05/15/2015 - "In a phase I study published in Clinical Cancer Research in March 2002, romidepsin (depsipeptide), a potent HDAC inhibitor, was found to be tolerable, with a side effect profile that was later understood to be characteristic of this class of agents. "
08/15/2013 - "Although there were no objective responses with romidepsin alone, this schedule may be useful for developing combination studies in solid tumors."
08/15/2013 - "Phase I trial of a new schedule of romidepsin in patients with advanced cancers."
12/01/2012 - "A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. "
|2.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
02/20/2012 - "The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). "
02/01/2014 - "Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials."
01/01/2014 - "Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses."
02/20/2012 - "Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy."
06/02/2011 - "Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma."
|3.||T-Cell Lymphoma (Lymphoma, T Cell)
08/01/2011 - "As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies."
08/01/2013 - "These initial results observed with single-agent romidepsin provide a foundation for exploring combination strategies and demonstrates proof-of-principle that other such drugs with similar mechanisms of action may be effective in T-cell lymphoma. "
05/16/2013 - "Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. "
12/01/2010 - "The efficacy and safety profile of romidepsin in clinical trials in T-cell lymphoma is reviewed, and emerging data on single-agent and combination strategies in myeloid and B-lymphoid malignancies is outlined. "
11/10/2009 - "On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. "
|4.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
10/10/2010 - "The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL). "
12/01/2013 - "Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. "
10/01/2012 - "Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. "
10/10/2010 - "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma."
10/01/2015 - "Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma."
10/10/2010 - "Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL."
10/01/2012 - "Romidepsin has shown an improvement in duration of response and pruritus over traditional therapy. "
02/01/2013 - "In a phase 2 study of romidepsin in patients with CTCL (GPI-04-0001), clinically meaningful reduction in pruritus (CMRP) was evaluated as an indicator of clinical benefit by using a patient-assessed visual analog scale. "
02/01/2013 - "Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin."
02/01/2013 - "To determine the effect of romidepsin alone, confounding pruritus treatments including steroids and antihistamines were prohibited. "
|1.||Histone Deacetylase Inhibitors
|3.||vorinostat (suberoylanilide hydroxamic acid)
|6.||Asp(5)- oxytocin (OXA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|5.||Homologous Transplantation (Allograft)